Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 18/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 18/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 15/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4338358 | 0.92 | OPRK1 (0.54) | OPRK1OPRL1OPRM1OPRD1 | |
| SCHEMBL4318202 | 0.91 | OPRK1 (0.59) | OPRK1OPRL1OPRM1OPRD1 | |
| SCHEMBL4330047 | 0.90 | OPRK1 (0.52) | OPRK1OPRL1OPRM1OPRD1 | |
| SCHEMBL4330965 | 0.87 | OPRK1 (0.55) | OPRK1OPRL1OPRM1OPRD1 | |
| SCHEMBL4327424 | 0.87 | OPRK1 (0.55) | OPRK1OPRL1OPRM1OPRD1 | |
| SCHEMBL4331164 | 0.86 | OPRK1 (0.54) | OPRK1OPRL1OPRM1OPRD1 | |
| SCHEMBL4326527 | 0.86 | OPRK1 (0.54) | OPRK1OPRL1OPRM1OPRD1 | |
| SCHEMBL4322682 | 0.85 | OPRK1 (0.52) | OPRK1OPRL1OPRM1OPRD1 | |
| SCHEMBL4329477 | 0.82 | OPRK1 (0.72) | OPRK1OPRL1OPRM1OPRD1 | |
| SCHEMBL4329074 | 0.75 | MEN1 (0.49) | OPRK1OPRL1OPRM1OPRD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | OPRK1 169/4885OPRL1 96/4885OPRM1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.